Provided by Tiger Trade Technology Pte. Ltd.

Johnson & Johnson

264.74
-2.8300-1.06%
Post-market: 265.090.3500+0.13%19:59 EDT
Volume:6.34M
Turnover:1.69B
Market Cap:637.84B
PE:30.66
High:268.48
Open:267.91
Low:264.51
Close:267.57
52wk High:281.07
52wk Low:182.94
Shares:2.41B
Float Shares:2.40B
Volume Ratio:1.06
T/O Rate:0.26%
Dividend:5.24
Dividend Rate:1.98%
EPS(TTM):8.64
EPS(LYR):11.03
ROE:25.74%
ROA:8.59%
PB:7.51
PE(LYR):23.99

Loading ...

Pharmaceutical Stocks Jump. Moderna, Eli Lilly up over 3%; Novavax, Pfizer up Around 2%; Merck, Novo Nordisk up over 1%

Tiger Newspress
·
Sep 24

Alert on EOG CFO Appointment Incorrectly Tagged to J&J Withdrawn

Reuters
·
Sep 24

EOG Resources Announces Ann Janssen's Retirement and Jeff Hibbard as Next CFO

THOMSON REUTERS
·
Sep 24

Johnson & Johnson (JNJ) Receives a Buy from RBC Capital

TIPRANKS
·
Sep 24

Medtronic PLC Stock Underperforms Wednesday When Compared to Competitors

Dow Jones
·
Sep 24

Johnson & Johnson Says New Analysis of Ongoing Phase 3 Trial Data Supports Potential of Multiple Myeloma Combination Therapy

MT Newswires Live
·
Sep 23

J&J Says New Model-Based Analysis Further Supports the Potential of Tecvayli Plus Darzalex Faspro

Reuters
·
Sep 23

Johnson & Johnson: Phase 3 MajesTEC-3 study shows ‘sustained’ disease control

TIPRANKS
·
Sep 23

J&J Says MajesTEC-3 Analysis Projects Near-General-Population Mortality Risk for Tecvayli-Darzalex Combo in Early Relapsed Myeloma

Reuters
·
Sep 23

J&J - Tecvayli Plus Darzalex Faspro Reduces Multiple Myeloma Progression Risk by 90% Versus Standard of Care

THOMSON REUTERS
·
Sep 23

New Model-Based Analysis Further Supports the Potential of Tecvayli® (Teclistamab-Cqyv) Plus Darzalex Faspro® (Daratumumab and Hyaluronidase-Fihj) to Redefine Long-Term Survival Expectations in Early Line Relapsed/Refractory Multiple Myeloma

THOMSON REUTERS
·
Sep 23

J&J - Analysis Estimates 87% of Tecvayli Plus Darzalex Faspro Patients Have Comparable Mortality Risk to General Population

THOMSON REUTERS
·
Sep 23

Kimberly-Clark Offers Remedies in Bid for EU Approval of Kenvue Deal

Reuters
·
Sep 23

Medtronic PLC Stock Underperforms Tuesday When Compared to Competitors

Dow Jones
·
Sep 23

Johnson & Johnson's Caplyta Has More Than $5 Billion Peak Sales Potential, UBS Says

MT Newswires Live
·
Sep 23

Dow Falls 134 Points on Losses for Shares of Cisco, JPMorgan Chase

Dow Jones
·
Sep 22

DePuy Synthes Showcases Next-Generation Trauma Innovations at OTA 2026

Reuters
·
Sep 22

J&J DePuy Synthes to Showcase Next-Generation Trauma Devices at Orthopaedic Trauma Association Annual Meeting

Reuters
·
Sep 22

Michael Yee Reiterates Buy on JNJ, Maintains $320 Price Target on Caplyta’s Strong Bipolar Mania Prospects

TIPRANKS
·
Sep 22

Biogen Inc. Stock Outperforms Competitors on Strong Trading Day

Dow Jones
·
Sep 22